BiologicalDrug
ANTI-GD2 monoclonal antibody 3F8 clinical trials
Also written monoclonal antibody 3F8.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 1994
How studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2005 (2)
| Year | Studies |
|---|---|
| 1994 | 1 |
| 1995 | 1 |
| 1999 | 1 |
| 2001 | 1 |
| 2005 | 2 |
| 2010 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 9
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ANTI-GD2 monoclonal antibody 3F8 is read from its arms, and is right about nine times in ten.
Testing it · 9
- Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic NeuroblastomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00492167Written as monoclonal antibody 3F8
- High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell TransplantationCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT01183416Written as 3F8 monoclonal antibody and 13-cis-Retinoic Acid
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk NeuroblastomaCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT01183429Written as 3F8 and 13-cis-retinoic acid
- Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With NeuroblastomaCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00004110Written as monoclonal antibody 3F8
- Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed NeuroblastomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00450307Written as monoclonal antibody 3F8
- Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With NeuroblastomaCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00002634Written as monoclonal antibody 3F8
- Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced NeuroblastomaCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00002560Written as monoclonal antibody 3F8
- Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second RemissionCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00002458Written as monoclonal antibody 3F8
- Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic NeuroblastomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00037011Written as monoclonal antibody 3F8
Codes
What other systems call ANTI-GD2 monoclonal antibody 3F8 · ClinicalTrials.gg INT014667
- UNII (FDA) 3GFS72WN4MANTI-GD2 MONOCLONAL ANTIBODY 3F8One source FDA
- NCI Thesaurus C2370Monoclonal Antibody 3F8One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3GFS72WN4M | ANTI-GD2 MONOCLONAL ANTIBODY 3F8 | One source FDA |
| NCI Thesaurus | C2370 | Monoclonal Antibody 3F8 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.